Federal agency BARDA grants approximately $10 million to RIVANNA for expediting the evolution of the CADe/x AI component in Accuro XV medical device.
In a significant development, RIVANNA, a commercial-stage medical device innovator and manufacturer based in Charlottesville, VA, has been granted nearly $10 million by the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of the CADe/x AI module for Accuro XV, their next-generation ultrasound platform for bone and 3D soft tissue imaging.
The funding received is primarily for the advancement of this cutting-edge technology, which is designed to help even novice users interpret ultrasound images and diagnose fractures with greater confidence. CADe/x will serve as a foundational component of Accuro XV, a system that offers early- and late-stage comprehensive imaging solutions for point-of-care spinal needle interventions, fracture diagnostics, and soft tissue diagnostics.
Will Mauldin, Ph.D., who serves as Chairman, CEO, and Co-founder of RIVANNA, leads the company in developing and commercializing world-first imaging-based medical technologies that aim to improve global standards of care. The project is supported by federal funds from the U.S. Department of Health and Human Services, ASPR, and BARDA, under contract number 75A50121C00035.
Accuro XV is expected to transform care delivery by accelerating the diagnosis of low-severity injuries, reducing unnecessary referrals for X-rays, and freeing up valuable imaging and physician resources for higher-acuity cases. The system may provide significant workflow efficiencies that enable faster, more confident clinical decision-making.
In addition, the platform has the potential to support more accurate triage in emergency departments by enabling early identification of soft tissue injuries, facilitating faster and more informed treatment decisions. Once deployed, Accuro XV is anticipated to revolutionise care delivery, particularly in emergency settings.
Accuro XV will also feature just-in-time training and automated image acquisition and interpretation, streamlining adoption in clinical settings. The AI-enabled decision assistance for fracture triage, provided by Accuro XV, is intended to help healthcare providers rapidly detect skeletal fractures and soft tissue injuries.
For more information about BARDA, visit https://www.medicalcountermeasures.gov. The original content of the press release can be viewed at https://www.prnewswire.com/news-releases/barda-awards-nearly-10-million-to-rivanna-to-accelerate-development-of-cadex-ai-module-for-accuro-xv-302516493.html.
The press release was issued by RIVANNA, and you can send an email for more information at Send an email.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
